A medical answer to a grey market.
Peptika is the first European medical platform for legal magistral peptide therapies. We exist because European patients deserve a framework that treats peptide therapy with the same care, scrutiny and accountability as any other prescribed medicine.
Four non-negotiable commitments.
Patient-named, always
No anonymous shipments. Every preparation is compounded against a valid Rx, in a patient's name.
Physician autonomy
Doctors retain full clinical authority. They can decline any request. If they do, your products are fully refunded — the €49 consultation fee covers the medical review and is not refunded.
Independent quality
Every batch is tested for sterility, endotoxins, identity, purity and heavy metals before release. CoAs uploaded automatically.
European by design
EU-licensed physicians. EU-GMP cleanrooms. EU cold-chain logistics. EU data residency. No grey-market shortcuts.
From research-only to magistral medicine.
- 2025
The research-only problem
European patients started seeking peptide therapies en masse — but every product on the market shipped under a 'Research Use Only' disclaimer. No prescription. No testing. No accountability.
- 2025
Sanjow Group chooses healthcare
Sanjow Group, a European subscription-commerce group operating across consumer health adjacents, decides to apply pharmaceutical-grade infrastructure to the peptide space.
- 2026
The platform
Phoenix Cluster B.V. is incorporated in the Netherlands to operate Europe-wide under Article 5(1) of Directive 2001/83/EC. Medical network onboarded, GMP-pharmacy partnerships and cold-chain logistics integrated, and the consultation platform brought live across the EU/EEA.